Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Organon & Co.

< Previous 1 2 Next >
Organon Appoints Ramona A. Sequeira to the Company’s Board of Directors
From Organon & Co.
Via Business Wire
Tickers OGN
Organon To Report First Quarter 2025 Results and Host Conference Call on May 1, 2025
From Organon & Co.
Via Business Wire
Tickers OGN
Organon Acquires TOFIDENCE™ (tocilizumab-bavi), a Commercialized Biosimilar to ACTEMRA® (tocilizumab) Injection, for Intravenous Infusion in the U.S.
From Organon & Co.
Via Business Wire
Tickers OGN
European Medicines Agency (EMA) Validates Henlius and Organon Filing for Perjeta® (pertuzumab) Biosimilar Candidate HLX11
From Organon & Co.
Via Business Wire
Tickers OGN
New Analysis of Organon’s VTAMA® (tapinarof) cream, 1% Phase 3 Data Shows Atopic Dermatitis Disease Activity Remained Low After Treatment-Free Interval in Adults and Children 2 Years of Age and Older
From Organon & Co.
Via Business Wire
Tickers OGN
Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2024
From Organon & Co.
Via Business Wire
Tickers OGN
Organon To Report Fourth Quarter and Full Year 2024 Results and Host Conference Call on February 13, 2025
From Organon & Co.
Via Business Wire
Tickers OGN
Organon To Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Organon & Co.
Via Business Wire
Tickers OGN
FDA Approves VTAMA® (tapinarof) cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older
From Organon & Co.
Via Business Wire
Tickers OGN
Update on FDA Review of VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older
From Organon & Co.
Via Business Wire
Tickers OGN
Organon Reports Results for the Third Quarter Ended September 30, 2024
From Organon & Co.
Via Business Wire
Tickers OGN
US FDA Accepts Biologics License Application (BLA) for HLX14, Biosimilar Candidate of PROLIA/XGEVA (denosumab)
From Organon & Co.
Via Business Wire
Tickers OGN
Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
From Organon & Co.
Via Business Wire
Tickers OGN
Organon to Report Third Quarter 2024 Results and Host Conference Call on October 31, 2024
From Organon & Co.
Via Business Wire
Tickers OGN
Primary Endpoint Met in Phase 3 Comparative Clinical Study of Perjeta® (pertuzumab) Biosimilar Candidate HLX11
From Organon & Co.
Via Business Wire
Tickers OGN
Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
From Organon & Co.
Via Business Wire
Tickers OGN
Organon & Lilly Expand Migraine Commercialization Agreement to 11 Additional Markets
From Organon & Co.
Via Business Wire
Tickers OGN
Organon Reports Results for the Second Quarter Ended June 30, 2024
From Organon & Co.
Via Business Wire
Tickers OGN
Organon To Report Second Quarter 2024 Results and Host Conference Call on August 6, 2024
From Organon & Co.
Via Business Wire
Tickers OGN
European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14
From Organon & Co.
Via Business Wire
Tickers OGN
Organon Announces Pricing of $1.0 Billion Senior Notes Offering
From Organon & Co.
Via Business Wire
Tickers OGN
Organon Announces Proposed $1.0 Billion Senior Notes Offering
From Organon & Co.
Via Business Wire
Tickers OGN
Organon Reports Results for the First Quarter Ended March 31, 2024
From Organon & Co.
Via Business Wire
Tickers OGN
Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024
From Organon & Co.
Via Business Wire
Tickers OGN
Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints
From Organon & Co.
Via Business Wire
Tickers OGN
Organon Announces HADLIMA™ (adalimumab-bwwd) Has Been Exclusively Selected by the US Department of Veterans Affairs (VA), Replacing HUMIRA on Its National Formulary
From Organon & Co.
Via Business Wire
Tickers OGN
Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2023
From Organon & Co.
Via Business Wire
Tickers OGN
Organon To Report Fourth Quarter and Full Year Results and Host Conference Call on February 15, 2024
From Organon & Co.
Via Business Wire
Tickers OGN
Organon’s XACIATO™ (clindamycin phosphate) Vaginal Gel 2% Available Nationwide to Treat Bacterial Vaginosis (BV) in Females Aged 12 and Older
From Organon & Co.
Via Business Wire
Tickers OGN
Organon affirms 2023 revenue and Adjusted EBITDA guidance and provides 2024 outlook
From Organon & Co.
Via Business Wire
Tickers OGN
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.